|
CN103755721A
|
|
Purification method of (S)-clopidogrel
|
|
CN103760256A
|
|
Method for separating and measuring olmesartan medoxomil intermediate related substances by liquid chromatography
|
|
CN103554081A
|
|
Preparation method of naratriptan impurity B
|
|
CN103570641A
|
|
Preparation method of loxapine and key intermediate of loxapine
|
|
CN103467376A
|
|
New method for preparation of meptazinol hydrochloride critical impurity
|
|
CN103467377A
|
|
Preparation method of meptazinol hydrochloride critical impurity
|
|
CN103230383A
|
|
Calcium dobesilate capsule composition and preparation method thereof
|
|
CN103211777A
|
|
Pharmaceutic preparation of duloxetine hydrochloride and preparation method thereof
|
|
CN103070829A
|
|
Medicine composition including pramipexole and active ingredients of medicinal salt and preparation method thereof
|
|
CN102846608A
|
|
Pharmaceutical composition containing amlodipine and atorvastatin calcium, and preparation method thereof
|
|
CN102846541A
|
|
Pramipexole oral liquid and preparation method thereof
|
|
CN102838527A
|
|
Novel preparation method of lercanidipine hydrochloride
|
|
CN103142541A
|
|
Stable montelukast sodium capsule
|
|
CN103565771A
|
|
Oral solid preparation containing indissolvable drug minodronic acid
|
|
CN102854260A
|
|
Method for separating and determining naproxcinod and optical isomers thereof by liquid chromatography
|
|
CN102850260A
|
|
Method for preparing hydrochloric acid lercanidipine impurities
|
|
CN102600183A
|
|
Furosemide and spirolactone composition for promoting furosemide to be dissolved out and preparation method of furosemide and spirolactone composition
|
|
CN102653544A
|
|
Synthesizing and refining method of 2-acetoxyl-5-[5-bromo-1-(2-fluorophenyl)-2-oxoamyl]-4,5,6,7-thiophane[3,2-c]pyridine
|
|
CN102626410A
|
|
Pharmaceutical composition containing roflumilast
|
|
CN102525878A
|
|
Tranexamic acid sustained-release solid composition and preparation method thereof
|
